Related Experiment Videos
Evaluation of the REMEDi drug profiling system
P Demedts1, A Wauters, F Franck
1A. Z. Middelheim, Laboratorium voor Klinische Scheikunde en Toxicologie, Antwerpen, Belgium.
European Journal of Clinical Chemistry and Clinical Biochemistry : Journal of the Forum of European Clinical Chemistry Societies
|May 1, 1994
Summary
The Bio-Rad REMEDi Drug Profiling System moderately screened drugs, detecting 80% of amphetamines and 68% of tricyclic antidepressants. REMeDi is a useful complementary tool for clinical toxicology, expanding drug detection and providing rapid reports.
Area of Science:
- Clinical Toxicology
- Forensic Chemistry
- Analytical Chemistry
Background:
- Immunoassays and standard chromatographic methods are mainstays in toxicological analysis.
- There is a need for rapid screening and expanded drug coverage in clinical toxicology.
Purpose of the Study:
- To evaluate the performance of the Bio-Rad REMEDi Drug Profiling System.
- To compare REMeDi with immunoassays and standard chromatographic techniques.
- To assess REMeDi's utility as a complementary tool in clinical toxicology.
Main Methods:
- Analysis of 116 samples (78 urines, 38 stomach contents).
- Comparison of REMeDi system with immunoassays, High-Performance Liquid Chromatography (HPLC), Gas Chromatography with Nitrogen-Phosphorus Detection (GC/NPD), and Gas Chromatography-Mass Spectrometry (GC/MS).
Main Results:
- REMEDi showed moderate performance as a screening method compared to immunoassays.
- Confirmation rates for REMeDi were 35% compared to 80% for conventional methods.
- REMEDi detected 53 additional compounds not identified by other methods, particularly in amphetamine and tricyclic antidepressant groups.
Conclusions:
- REMEDi is a valuable complementary technique in clinical toxicology.
- It expands the range of detectable drugs beyond immunoassays.
- REMEDi offers rapid preliminary reporting for emergency situations.